IL105503A - Carbon peptide couplets capable of eliciting an immune response of T cells - Google Patents

Carbon peptide couplets capable of eliciting an immune response of T cells

Info

Publication number
IL105503A
IL105503A IL10550393A IL10550393A IL105503A IL 105503 A IL105503 A IL 105503A IL 10550393 A IL10550393 A IL 10550393A IL 10550393 A IL10550393 A IL 10550393A IL 105503 A IL105503 A IL 105503A
Authority
IL
Israel
Prior art keywords
peptide
conjugate
cells
carbohydrate
component
Prior art date
Application number
IL10550393A
Other languages
English (en)
Hebrew (he)
Other versions
IL105503A0 (en
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL105503A0 publication Critical patent/IL105503A0/xx
Publication of IL105503A publication Critical patent/IL105503A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL10550393A 1992-04-28 1993-04-22 Carbon peptide couplets capable of eliciting an immune response of T cells IL105503A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv

Publications (2)

Publication Number Publication Date
IL105503A0 IL105503A0 (en) 1993-08-18
IL105503A true IL105503A (en) 1999-05-09

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10550393A IL105503A (en) 1992-04-28 1993-04-22 Carbon peptide couplets capable of eliciting an immune response of T cells

Country Status (19)

Country Link
US (2) US5807559A (is)
EP (1) EP0675733B1 (is)
JP (1) JPH07506358A (is)
CN (1) CN1096032A (is)
AT (1) ATE197903T1 (is)
AU (1) AU676679B2 (is)
CA (1) CA2134097A1 (is)
DE (1) DE69329735T2 (is)
DK (1) DK0675733T3 (is)
ES (1) ES2155070T3 (is)
GR (1) GR3035501T3 (is)
IL (1) IL105503A (is)
IS (1) IS4010A (is)
MA (1) MA22885A1 (is)
MY (1) MY108864A (is)
PT (1) PT675733E (is)
SI (1) SI9300223A (is)
TN (1) TNSN93045A1 (is)
WO (1) WO1993021948A1 (is)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (en) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Carbohydrate-specific cytolytic t cells
PT969873E (pt) * 1997-03-27 2006-09-29 Pasteur Institut Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
EP0996455B1 (en) * 1997-04-16 2009-12-16 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered (2,6)-st epitopes, methods of preparation and uses thereof
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
CA2324616A1 (en) * 1998-03-25 1999-09-30 Sloan-Kettering Institute For Cancer Research Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
JP5111705B2 (ja) 1999-08-20 2013-01-09 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
KR20050099536A (ko) * 2003-02-06 2005-10-13 트리펩 아베 글리코실화된 특이성 교환체
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US20130195800A1 (en) 2010-03-23 2013-08-01 Intrexon Corporation Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
EP2500033A1 (en) 2011-03-17 2012-09-19 Institut Pasteur Method for preparing muliple antigen glycopeptide carbohydrate conjugates
AU2012333211A1 (en) 2011-06-28 2013-12-19 Inovio Pharmaceuticals, Inc. A miniminally invasive dermal electroporation device
EP2606897A1 (en) * 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
WO2019014456A1 (en) * 2017-07-12 2019-01-17 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS HAVING A MUTATION H3K27M
WO2020163695A1 (en) 2019-02-07 2020-08-13 Board Of Regents, The University Of Texas System Aspergillus antigen chimeric receptors and use thereof
CA3130671A1 (en) 2019-02-07 2020-08-13 Board Of Regents, The University Of Texas Systems Glucuronoxylomannan (gxm) receptor chimeric antigen receptors and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (en) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Enhancement of the cellular immune response
WO1989006974A2 (en) * 1988-02-01 1989-08-10 Praxis Biologics, Inc. T-cell epitope as carriers molecule for conjugate vaccines
JPH03504493A (ja) * 1988-02-12 1991-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞性免疫の発生及び操作のための合成ペプチドの使用
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (en) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
CA2067124A1 (en) * 1989-08-28 1991-03-01 Patricia L. Domen Cationized carriers for immunogen production
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
IL105503A0 (en) 1993-08-18
MA22885A1 (fr) 1993-12-31
US6033669A (en) 2000-03-07
CN1096032A (zh) 1994-12-07
EP0675733A1 (en) 1995-10-11
JPH07506358A (ja) 1995-07-13
AU4274693A (en) 1993-11-29
ES2155070T3 (es) 2001-05-01
CA2134097A1 (en) 1993-11-11
EP0675733B1 (en) 2000-12-06
AU676679B2 (en) 1997-03-20
US5807559A (en) 1998-09-15
ATE197903T1 (de) 2000-12-15
TNSN93045A1 (fr) 1994-03-17
DE69329735T2 (de) 2001-08-02
DK0675733T3 (da) 2001-05-07
GR3035501T3 (en) 2001-06-29
MY108864A (en) 1996-11-30
SI9300223A (en) 1994-03-31
DE69329735D1 (de) 2001-01-11
IS4010A (is) 1993-10-29
PT675733E (pt) 2001-05-31
WO1993021948A1 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
EP0675733B1 (en) Peptide-carbohydrate conjugates generating t-cell immunity
Galli-Stampino et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity
Yin et al. Recent development in carbohydrate based anticancer vaccines
Kuduk et al. Synthetic and immunological studies on clustered modes of mucin-related Tn and TF O-linked antigens: The preparation of a glycopeptide-based vaccine for clinical trials against prostate cancer
US7998486B2 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
Yin et al. Significant impact of immunogen design on the diversity of antibodies generated by carbohydrate-based anticancer vaccine
Karmakar et al. Synthesis of a liposomal MUC1 glycopeptide-based immunotherapeutic and evaluation of the effect of L-rhamnose targeting on cellular immune responses
US6660714B1 (en) α-O-linked glycoconjugates, methods of preparation and uses thereof
Allen et al. A second generation synthesis of the MBr1 (Globo‐H) breast tumor antigen: New application of the N‐pentenyl glycoside method for achieving complex carbohydrate protein linkages
Hossain et al. Augmenting vaccine immunogenicity through the use of natural human anti-rhamnose antibodies
Sarkar et al. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes
Becker et al. Synthetic glycopeptides from the mucin family as potential tools in cancer immunotherapy
US20240216491A1 (en) Neoglycoconjugates as vaccines and therapeutic tools
Hogervorst et al. C-mannosyl lysine for solid phase assembly of mannosylated peptide conjugate cancer vaccines
JP2012132025A (ja) 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
WO2009101205A2 (en) Immunogenic control of tumours and tumour cells
Henningsson et al. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo
US20070116727A1 (en) Vaccines directed to cancer-associated carbohydrate antigens
US6544952B1 (en) Synthesis of glycoconjugates of the globo-H epitope and uses thereof
Ritter et al. Analysis of the antibody response to immunization with purified O‐acetyl GD3 gangliosides in patients with malignant melanoma
Rashidijahanabad et al. Stereoselective Synthesis of Sialyl Lewisa Antigen and the Effective Anticancer Activity of Its Bacteriophage Qβ Conjugate as an Anticancer Vaccine
Marqvorsen et al. Going native: synthesis of glycoproteins and glycopeptides via native linkages to study glycan-specific roles in the immune system
Kunz Synthetic glycopeptides for the development of tumour‐selective vaccines
Bay et al. Induction of a melanoma‐specific antibody response by a monovalent, but not a divalent, synthetic GM2 neoglycopeptide
Franco Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions

Legal Events

Date Code Title Description
FF Patent granted
RH1 Patent not in force